alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Page 46229]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-21538]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated April 17, 2009, and published in the Federal 
Register on April 29, 2009 (74 FR 19595), Almac Clinical Services, 
Inc., (ASCI), 2661 Audubon Road, Audubon, Pennsylvania 19403, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as an importer of the basic classes of controlled 
substances listed in schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Oxycodone (9143)...........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to import small quantities of the listed 
controlled substances in dosage form to conduct clinical trials.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the 
registration of Almac Clinical Services Inc. to import the basic 
classes of controlled substances is consistent with the public 
interest, and with United States obligations under international 
treaties, conventions, or protocols in effect on May 1, 1971, at this 
time. DEA has investigated Almac Clinical Services Inc. to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with State and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic classes of controlled 
substances listed.

    Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-21538 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P
HomeIndonesia

# Indonesia

200 items

        -    Media Note  		Special Representative for Commercial and Business Affairs Morgenthau’s Travel to Singapore, Vietnam, and Indonesia	  April 5, 2024 
        -    Department Press Briefing  		Department Press Briefing – March 20, 2024	  Vedant PatelMarch 20, 2024Washington, D.C. 
        -    Press Statement  		Congratulations to Indonesian President-Elect Subianto	  Antony J. BlinkenMarch 20, 2024 
        -    Media Note  		Under Secretary Zeya’s Travel to the Republic of Korea and Indonesia	  March 15, 2024 
        -    Special Needs Profile  		Jakarta, Indonesia: Jakarta Intercultural School: 2024 Special Needs Profile	  February 23, 2024 
        -    Department Press Briefing  		Department Press Briefing – February 14, 2024	  Matthew MillerFebruary 14, 2024Washington, D.C. 
        -    Press Statement  		Election in Indonesia	  Matthew MillerFebruary 14, 2024 
        -    Special Needs Profile  		Surabaya, Indonesia: Surabaya Intercultural School: 2024 Special Needs Profile	  February 9, 2024 
        -    Readout  		Deputy Secretary Verma’s Engagements in Indonesia	  February 2, 2024 
        -    Media Note  		Deputy Secretary for Management and Resources Verma’s Trip to  Australia, Fiji, and Indonesia	  January 26, 2024 

123…20next page

Back to Top
Back
      to Form 10-Q


Exhibit
      32.1





**Certification
      of CEO Pursuant to 18 U.S.C. Section 1350**





Pursuant
      to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002, the undersigned certifies that (1) this Quarterly
      Report of Capital City Bank Group, Inc. (the "Company") on Form 10-Q for the
      period ended September 30, 2006, as filed with the Securities and Exchange
      Commission on the date hereof (this "Report"), fully complies with the
      requirements of Section 13(a) of the Securities Exchange Act of 1934, as
      amended, and (2) the information contained in this Report fairly presents,
      in
      all material respects, the financial condition of the Company and its results
      of
      operations as of and for the periods covered therein.








/s/
                William G. Smith, Jr.William
                G. Smith, Jr.Chairman,
                President, andChief
                Executive Officer





Date:
      November 9, 2006








A
      signed
      original of this written statement required by Section 906, or other document
      authenticating, acknowledging or otherwise adopting the signature that appears
      in typed form within the electronic version of this written statement required
      by Section 906, has been provided to the Company and will be retained by the
      Company and furnished to the Securities and Exchange Commission or its staff
      upon request.
Editorial Note on Part 414
Editorial Note: Nomenclature changes to part 414 appear at 60 FR 50442, Sept. 29, 1995, and 60 FR 53877, Oct. 18, 1995.

§ 414.1245 Scoring methods for the value-based payment modifier using the quality-tiering approach. For each quality of care and cost measure, a standardized score is calculated for each group and solo practitioner subject to the value-based payment modifier by dividing— ( a ) The difference between their performance rate and the benchmark, by
( b ) The measure's standard deviation.
[77 FR 69368, Nov. 16, 2012, as amended at 79 FR 68007, Nov. 13, 2014]
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000702756
<NAME> SEEQ TECHNOLOGY INC
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          SEP-30-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                            3974
<SECURITIES>                                         0
<RECEIVABLES>                                     8475
<ALLOWANCES>                                       240
<INVENTORY>                                       5352
<CURRENT-ASSETS>                                 17929
<PP&E>                                           12004
<DEPRECIATION>                                    7746
<TOTAL-ASSETS>                                   26435
<CURRENT-LIABILITIES>                             8776
<BONDS>                                           3466
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           302
<OTHER-SE>                                       13891
<TOTAL-LIABILITY-AND-EQUITY>                     26435
<SALES>                                          31338
<TOTAL-REVENUES>                                 31338
<CGS>                                            20680
<TOTAL-COSTS>                                    20680
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 240
<INCOME-PRETAX>                                   2939
<INCOME-TAX>                                        88
<INCOME-CONTINUING>                               2851
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      2851
<EPS-PRIMARY>                                     0.09
<EPS-DILUTED>                                     0.09
        

</TABLE>
EXHIBIT 14

         CONSENT OF JONES SIMKINS, P.C., COMPANY'S INDEPENDENT AUDITORS
           FOR THE YEARS ENDED DECEMBER 31, 2004 AND DECEMBER 31, 2003





                        CONSENT OF INDEPENDENT REGISTERED
                        ---------------------------------
                             PUBLIC ACCOUNTING FIRM
                             ----------------------

Utah Medical Products, Inc.

           We  consent  to  the   incorporation  by  reference  in  Registration
Statement  Nos.  33-24781,  33-44100,  33-89394,  and  33-89434 of Utah  Medical
Products, Inc. on Forms S-8 of our financial statement audit report and internal
control over financial reporting audit report dated January 17, 2005,  appearing
in this Annual Report on Form 10-K of Utah Medical Products,  Inc. for the years
ended December 31, 2004 and December 31, 2003.



/s/ Jones Simkins, P.C.


JONES SIMKINS, P.C.
Logan, Utah
March 16, 2005
HomeOffice of the SpokespersonPress Releases...First Trilateral Sanctions against Russian Cyber Actor

# 									First Trilateral Sanctions against Russian Cyber Actor							

Press Statement

Matthew Miller, Department Spokesperson

January 23, 2024

In coordination with Australia and the United Kingdom, the United States is designating a Russian cyber actor involved in the 2022 ransomware attack against an Australian healthcare insurer.  Today’s action, our first trilateral sanctions action using our respective cyber sanctions regimes, strengthens our partnership in the fight against malicious cyber actors.

Russia continues to provide a safe haven to ransomware actors and enable ransomware attacks by cultivating and co-opting criminal hackers who have launched disruptive ransomware attacks against U.S. and allied countries.  We will continue to stand with our partners to disrupt ransomware actors that threaten our economies and critical infrastructure.

*The Department of the Treasury is taking these actions pursuant to**Executive Order 13694**, as amended.  For more information on this designation, see Treasury’s**press release**.*

Tags

AustraliaBureau of East Asian and Pacific AffairsBureau of European and Eurasian AffairsCyber IssuesCyber SecurityCybersecurity ExchangeHealth CareOffice of the Coordinator for Cyber IssuesOffice of the SpokespersonRussiaSanctionsUnited Kingdom

## Related Articles

-  											 									
Read more
 

Back to Top
EX-10bf






Exhibit 10bf




FIRST AMENDMENT

TO

BRUSH ENGINEERED MATERIALS INC.

AMENDED AND RESTATED EXECUTIVE DEFERRED COMPENSATION PLAN II




                 The Brush Engineered Materials Inc. Amended and Restated Executive Deferred Compensation Plan
II (the “Plan”), adopted on July 29, 2008, is hereby amended in the following respects effective
January 1, 2008.


1. Section 2.2 of the Plan is amended and restated as follows:





2.2 Annual Excess Compensation means for a Plan Year a Participant’s Base Salary for
services performed during the Plan Year, performance compensation payable in the Plan Year
under the Brush Engineered Materials Inc. and Subsidiaries Management Performance
Compensation Plan, and incentive compensation payable in cash, cash equivalents, equity and
equity-based amounts in the Plan Year under the Brush Engineered Materials Inc. and
Subsidiaries Long-Term Incentive Plan, whether or not such compensation is reportable on Form
W-2 for the Plan Year, but only to the extent that such compensation exceeds the limit
imposed on compensation taken into account under the Brush Engineered Materials Inc. Savings
and Investment Plan by reason of Code Section 401(a)(17) as determined by the Plan
Administrator.



                 WITNESS WHEREOF, Brush Engineered Materials Inc. has caused this Amendment to be executed by
its duly authorized officer this 2nd day of February, 2009.



	 	 	 	 	 
	 	 	BRUSH ENGINEERED MATERIALS INC.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Michael C. Hasychak
	 

	 	Name:
	 	Michael C. Hasychak
	 

	 	Title:
	 	Vice President, Treasurer and Secretary
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM SULCUS
HOSPITALITY TECHNOLOGIES CORP.'S CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                           9,171
<SECURITIES>                                         0
<RECEIVABLES>                                   11,246
<ALLOWANCES>                                     1,852
<INVENTORY>                                      3,432
<CURRENT-ASSETS>                                24,343
<PP&E>                                           7,495
<DEPRECIATION>                                   5,212
<TOTAL-ASSETS>                                  40,638
<CURRENT-LIABILITIES>                           13,427
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        41,344
<OTHER-SE>                                    (15,471)
<TOTAL-LIABILITY-AND-EQUITY>                    40,638
<SALES>                                         14,465
<TOTAL-REVENUES>                                14,465
<CGS>                                            6,371
<TOTAL-COSTS>                                    6,371
<OTHER-EXPENSES>                                 7,649
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  25
<INCOME-PRETAX>                                    420
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                420
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       420
<EPS-PRIMARY>                                      .02
<EPS-DILUTED>                                      .02
        

</TABLE>
July 20th , 2010 

The Honorable Ray LaHood 

Secretary 

American Samoa ~ Visitors Bureau 

United States Department of Transportation 

1200 New Jersey Avenue, SE 

Washington, DC 205900 

Subject: Application of Aviation Services, Ltd. (dba Freedom Air) DOT-OST-2010-0153 

Talofa Secretary LaHood, 

I am writing in my capacity as Executive Director of the American Samoa Visitors Bureau to offer my 

support for Aviation Services, Ltd., (dba Freedom Air) application to engage in charter air 

transportation of passengers to and from Guam. 

As the United States' most southern territory in the world, American Samoa is one of the last 

untouched paradises of the Pacific region whose tourism industry is still very small, but beginning to 

take firm measures to grow the industry on island. 

As we attempt to grow our tourism sector, the American Samoa Visitors Bureau is keen to partner with 

travel industry members regionally and globally, and Freedom Air potentially as a partner can make a 

valuable contribution to our industry in the future. 

Having recently met with Freedom Air's General Manager, Joaquin L. Flores Jr., he outlined the 

company's intention to apply for a Certificate of Public Convenience and Necessity with your office to 

expand services from Guam to Asia. He has also indicated that charter services from Guam to American 

Samoa and other South Pacific nations are also being considered for the future. 

For us, the potential for charter operations will make a viable contribution to our economy and 

industry, bringing in visitors who will contribute valuable foreign exchange earnings, and at the same 

time creating employment for our people in the Territory. 

With this overall goal in mind I hope your Department looks favorably upon this application and we look 

forward to working with Freedom Air in the future. 

Fa'afetai tele lava, thank you. 

Soifua 

Executive Director 

PO Box 4240, Pago Pago, American Samoa 96799 

Ph: 1-684-6999805, Fax: 1-684-6999806, Email: infO®americansamoa.travel, Website: www.americansamoa.travel 

•
<PAGE>

                                                                        REDACTED

                                                                  EXHIBIT 10.313



                      **CONFIDENTIAL TREATMENT REQUESTED**

                                    AMENDMENT

         This agreement is entered into by and between CHIRON CORPORATION, a
Delaware corporation ("Chiron") and GEN-PROBE INCORPORATED, a Delaware
corporation ("Gen-Probe").

                                    RECITALS

WHEREAS, Chiron and Gen-Probe signed an agreement on June 11, 1998 with
respect to Products for the Blood Screening Field and [PROVISION ASSIGNED]
(the "Agreement").

         WHEREAS, the parties desire to amend the Agreement as set forth in this
Amendment in order to facilitate the purposes of the Agreement.

                                    AGREEMENT

         In consideration of the facts recited above and the mutual commitments
set forth below, the parties agree as follows:

         1.       Article 14 of the Agreement shall be and is hereby amended to
read as follows:

                  "In consideration for the rights originally granted to Chiron
         by this Agreement with respect to TMA and HPA, Chiron shall pay to
         Gen-Probe, [PROVISION ASSIGNED], the following nonrefundable amounts
         upon the occurrence of each event set forth below:

                  (1) [CONFIDENTIAL TREATMENT REQUESTED]; and

                  (2) [CONFIDENTIAL TREATMENT REQUESTED]:

                         (a) (i) [CONFIDENTIAL TREATMENT REQUESTED]

                         (b) [CONFIDENTIAL TREATMENT REQUESTED].

                  (3) [CONFIDENTIAL TREATMENT REQUESTED].

                  (4) [CONFIDENTIAL TREATMENT REQUESTED].



<PAGE>



         2.       Except as expressly amended above, the Agreement shall remain
in full force and effect.

                  By the signatures of their authorized officers below,
Gen-Probe and Chiron adopt this amendment as of December 7, 1999.


CHIRON CORPORATION                    GEN-PROBE INCORPORATED


By       /s/ RAJEN DALAL              By       /s/ HENRY L. NORDHOFF
         ----------------                      ----------------------
                                               Henry L. Nordhoff
Title: President, Blood Testing                President and
         Chiron                                Chief Executive Officer




                                  Page 2 of 2
###### Editorial Note on Part 414

#### Editorial Note:

Nomenclature changes to part 414 appear at 60 FR 50442, Sept. 29, 1995, and 60 FR 53877, Oct. 18, 1995.

#### § 414.800 Purpose.

This subpart implements section 1847A of the Act by specifying the requirements for submission of a manufacturer's average sales price data for certain drugs and biologicals covered under Part B of Title XVIII of the Act that are paid under sections 1842(o)(1)(D), 1847A, and 1881(b)(13)(A)(ii) of the Act.
HomeCountries & Areas…Iran

# Iran

		Subscribe		                  -  View Fact SheetEmbassies & Consulates
Bureau of Near Eastern Affairs
International Travel Information
What you need to know before you go: visas, Embassy & Consulate locations, vaccinations, etc.
International Travel Information: Learn More Current Travel Advisories
Level 4: Do Not Travel
Learn More								U.S. Relationship																									These are excerpts from the U.S. Relations With Iran																			-  												U.S.-Iran Relations											 
													U.S.-Iran Relations													Switzerland is the U.S. protecting power and provides limited consular services to U.S. citizens in Iran. More information about the Islamic Republic of Iran is available from the Department of State and other sources.Discover More2022 Country Reports on Human Rights Practices2022 Report on International Religious Freedom2023 Trafficking in Persons Report
View all Department Reports and Publications
HighlightsApril 11, 2024
Department Press Briefing – April 11, 2024
April 8, 2024
Department Press Briefing – April 8, 2024
April 4, 2024
Designating Financial Supporters of Iran’s Ministry of Defense  
April 4, 2024
Condition (10)(C) Annual Report on Compliance with the Chemical Weapons Convention (CWC)
April 3, 2024
Department Press Briefing – April 3, 2024
							VIEW ALL NEWS						
Tags
Bureau of Near Eastern AffairsIranBack to Top- White House
- USA.gov
- Office of the Inspector General
- Archives
- Contact Us
follow usFacebookTwitterInstagramYouTubeFlickrGovDelivery- Privacy Policy
- Accessibility Statement
- Copyright Information
- FOIA
- No FEAR Act
U.S. Department *of* StateThe Lessons of 1989: Freedom and Our Future
# **Exhibit 10.8**

 

 

January 9, 2003

 

Mr. Joseph C. Christenson

President

PPT Vision, Inc.

12988 Valley View Road

Eden Prairie, MN   55344

 

Dear Joe:

 

             In response to our recentdiscussions about the potential capital requirements of PPT Vision, Inc.,  I hereby advise you that the Investorslisted below would be willing to provide $500,000-$750,000 of additional capital to the Company, depending uponthe Company’s needs, through April 30, 2004.

 

             I anticipate the investment wouldtake the form of one or more of (i) a working capital line of credit (ii) aconvertible note or debenture, (iii) preferred stock or (iv) common stock.  In connection to any line of credit or debtinstrument , a security interest in some or all of the Company’s assets,including intellectual property might be required.

 

             This loan or investment would bemade by one or more of the following Investors: (i) P R Peterson individually(including through the PR Peterson Keogh Plan), (ii) ESI Investment Company and(iii) Peterson Brothers Securities Company.

 

             I am available to meet with membersof management or the Company’s Board of Directors at your convenience tofinalize the terms of any financing.

 

| Very truly yours,     |
|-----------------------|
|                  |
| /s/ PETER R. PETERSON |   |
| P. R. Peterson        |

 

----
## BEFOR E TH E DEPARTMENT OF TRANSPORTATIO N WASHINGTON , D.C .
Agreement s Adopte dby th e Tariff s Conferenc e Docke t OST-2006 - 2428 7 Internationa

l Ai r Transpor t Associatio n
APPLICATIO N FO RAPPROVA L O F AGREEMENT S B Y TH E INTERNATIONA

L AI RTRANSPOR

T ASSOCIATIO N REQUES T T O WITHDRA W PENDIN G AGREEMEN T FRO M DOCKE T 2005-2202 9

lAT A REQUES T T O WITHDRA W AGREEMEN T APPROVE D DOCKE T OST-05-2202 9 ACTIO N DAT E Septembe r 23.201 1 Thi s approval an dgran t

o f antitrus t immunit y i s subject , where appiicable , 2 7 Marc h 200 6 to condition s previously imposed . Thi s actio n i s effectiv

e after 7 day s unles s apetitio n i s file dunde r 1 4 CF R385.3 0 Communication s wit h rCSpeC t t O o r arevie w i s undertal(e n o

n th e Department' s ow

n motion . I

n vie w o f th e tJ^i g documen t shoul db e SCn t

tO : agreement' s noncontroversial natur e an dth e avaiUbilit y o f th e abov e procedures , th e 21-d^<aerio di

n 14CEf < 3014 2 i s wai^ d 

## ( L/ t A ~A f /X ^ Dougla s Lavin

. —^1 ^ Regiona l Vic e Presiden

t - Nort h Americ a International Ai r

Transpor t Associatio n 1750KSt . N.W . #12 * Floo r Washington , D.C . 2000 6 (202 ) 293-929 2